Recursion Pharmaceuticals (RXRX) posted another year of accelerating losses, with net losses growing at 35.2% per year over the last five years. Despite ongoing red ink, revenue is forecast to climb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback